India, July 3 -- Delhi University (DU) has started Phase 2 of the Undergraduate (UG) admission process for the 2026-27 ...

The University of Delhi has announced the Phase 2 schedule for CSAS UG admissions. Key dates include the declaration of the ...

The makers of Cocktail 2 are set to redefine film promotions with an ambitious new initiative that goes beyond traditional trailer launches, city tours, and fan interactions. In what is being ...

With masks on their faces and bags in their hands, two individuals - a man and a woman - entered a Delhi professor's house on Wednesday (June 3), the day she was murdered. The two made an exit around ...

Upasna is an education journalist and subject matter expert with an extensive background in the competitive exam landscape. Currently contributing to the Exam Prep Section of Jagran Josh, Upasna ...

Through mobile heat relief units, relief was provided to approximately 2.65 lakh people across all 13 districts of Delhi between May 6 and May 23. NEW DELHI: Amid the scorching heat, the Delhi ...

Bristol Myers and Hengrui's $15.2 billion partnership, Takeda's massive layoffs and Daiichi Sankyo's global oncology ambition made our news this week. (sankai/iStoc /Getty Images Plus) Bristol Myers ...

Delhi Chief Minister Rekha Gupta on Thursday announced two days work from home for government offices, minimum use of vehicles, in line with Prime Minister Narendra Modi's appeal for fuel conservation ...

Jiangsu Hengrui Pharmaceutical, China’s largest drug company by market capitalisation, has signed a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) ...

NEW DELHI: Nearly 465 students of Shaheed Rajguru College of Applied Sciences for Women have been declared ineligible to appear for the upcoming end-semester examinations after failing to meet the ...

Bristol Myers Squibb has forged close ties with China's Hengrui Pharma, partnering across 13 programmes in oncology, haematology, and immunology in a deal that could be worth a massive $15.2 billion.

Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos faces new competition. A year ago, in the first quarter of 2025, BMS’ ...